Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy

Gerardo Rosati(Ospedale San Carlo), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alfonso De Stefano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Marianna Giampaglia(Ospedale San Carlo), Concetta Maria Porretto, Alessandro Cappetta(Ospedale San Bortolo), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Alfredo Colombo, Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Stefano Cordio(Ospedale San Carlo)

Biomedicines

April 30, 2022

10.3390/biomedicines10051035

Cited by 14

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

|The Lancet|2010|7.3k

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

|NEJM Evidence|2022|1.1k

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

|Journal of Clinical Oncology|2011|763

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

|The Lancet|2023|701

Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer

|Journal of Clinical Oncology|2000|452